Skip to Content

Glecaprevir / pibrentasvir Side Effects

For the Consumer

Applies to glecaprevir / pibrentasvir: oral tablet

Along with its needed effects, glecaprevir / pibrentasvir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Some side effects of glecaprevir / pibrentasvir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

For Healthcare Professionals

Applies to glecaprevir / pibrentasvir: oral tablet


The most common side effects reported with this drug in hepatitis C virus (HCV)-infected patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) were headache and fatigue. The most common side effects reported in HCV-infected patients with severe renal dysfunction were pruritus and fatigue.[Ref]

Nervous system

Very common (10% or more): Headache (up to 17%)

Rare (less than 0.1%): Transient ischemic attack[Ref]


Very common (10% or more): Pruritus (up to 17.3%)[Ref]


Very common (10% or more): Fatigue (up to 16%)

Common (1% to 10%): Asthenia[Ref]


Very common (10% or more): Nausea (up to 12%)

Common (1% to 10%): Diarrhea[Ref]


Common (1% to 10%): Elevated total bilirubin

Uncommon (0.1% to 1%): Direct hyperbilirubinemia[Ref]

Elevated total bilirubin (at least 2 times the upper limit of normal) was reported in 3.5% of patients; such elevations were seen in 1.2% of patients across phase 2 and 3 trials and were related to glecaprevir-mediated inhibition of bilirubin transporters and metabolism. Bilirubin elevations were asymptomatic, transient, and generally occurred early during therapy; these elevations were mainly indirect and not associated with ALT elevations. No jaundice was observed and total bilirubin levels decreased after completion of therapy.[Ref]


1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.